Unique, novel 
radiotracers and radiochemistry

Bringing nuclear imaging and innovative radiochemistry to the North West and beyond

© Medicines Discovery Catapult 2021. All rights reserved.

Our experts behind the scenes
Dr Juliana Maynard, Lead Scientist

Juliana has got over 13 years’ industry imaging experience. Before coming to MDC, Juliana worked at AstraZeneca in their preclinical imaging team for almost 10 years. After AstraZeneca, she set up Alderley Imaging with Alderley Park for 2 years before moving to MDC to enhance and increase their imaging capabilities.
Dr Michael Fairclough, Senior Scientist - Radiochemistry

Michael has worked in the field of PET radiochemistry for over 15 years, obtaining his PhD in radiochemistry from the University of Manchester focussing on PET radiochemistry for the investigation of pain and inflammation. Michael also holds an honorary lecture position at the University of Manchester teaching basic and advanced PET radiochemistry theory for MSc students.  
Our pre-clinical imaging platforms can be used to visualise in cells, tissues and rodents the biodistribution of molecules, track novel drug delivery and complex medicine modalities, and provide clear evidence of biomarker responses to novel drug candidates. We can access specialist in-vivo models and PET radiotracers to meet your specific programme needs. We are positioned to assist many UK innovators to advance their programmes with our high-quality data.
Strengthening our capabilities
We have relaunched radiochemistry at the Wolfson Molecular Imaging Centre (WMIC) in Manchester - our labs supplies hard-to-make radiochemicals to drug discovery biotechs and academic innovators – increasing the UK’s potential to discover new and better therapies for patients, faster.

Our 
in-vivo
 imaging and infrastructure, with WMIC’s heritage in radiochemistry, further strengthens the national PET Network. It also creates an opportunity for theranostics – an area of potentially significant impact – to flourish within the UK.
Dr Dhifaf Jasim, Senior Scientist - Radiochemistry

Dhifaf has 11 years of experience in the field of nanomedicine research with a PhD in Pharmacology/Nanomedicine from the University of Manchester. She has made, characterised, and labelled various nanoparticles and biomolecules with different tags whether for optical imaging or nuclear imaging purposes. As well as performing a huge amount of in vivo imaging (SPECT/CT, IVIS) and toxicology work with the aim of understanding the structure-activity relationships in vivo.
How we can support you

GE PETtrace cyclotron capable of producing the following radionuclides:

  • 18F fluoride (radioactive half-life 110 mins)
  • 11C (radioactive half-life 20 mins)

Automated Radiochemistry synthesis modules housed within 3 x Hot Cell  allowing for novel radiochemistry and novel radiotracers to be produced

2 x Shielded fume cupboard for manual radiochemistry and handling of externally sourced radionuclides such as zirconium-89 (radioactive half-life 78.4 hours)

2 x Radio-HPLC and Radio-TLC for analysis and QC of radiotracers

Ability to send radiotracers off site to academic facilities and SMEs

Need support with radiotracers?

We can support you with your radiotracers
Why choose us?
ADAPTABLE
Our Cyclotron allows us to produce 18F and 11C whenever we need, giving us the ability to make unique and novel radiotracers plus accomplish innovative radiochemistry and radiolabelling strategies.
EXPERTISE
Our team is dedicated to pre-clinical imaging and radiochemistry and has a wealth of relevant expertise to support you with your project. 
TECHNOLOGY
Dedicated PET radiochemistry with automated synthesis modules and analysis equipment to produce novel radiotracers and ensure they meet specifications required for PET imaging projects.  
How we've helped
We collaborated with the University of Leeds to support LUNAC Therapeutics in developing a next-generation anticoagulant.

The aim:
To develop a first-in-class drug to prevent the formation of a blood clot inside a blood vessel (thrombosis). To optimise and advance the discovery of a new class of highly specific anticoagulant compounds that block an activated clotting enzyme, Factor XII (FXIIa). For which there is strong evidence that inhibition will not increase the risk of bleeding.

How we supported:
We supported LUNAC with radiolabelling, purification and formulation of the 18F-fibrin binding peptide ([18F]FBP). Also supplying batches of [18F]FBP off-site to our labs at Alderley Park to use for in vivo
 PET imaging of thrombosis. The [18F]FBP binds to fibrin, a major component of thrombi - PET imaging with [18F]FBP allows quantitative imaging of the thrombi.
It’s been absolutely amazing working with MDC and the team...
Helen Philippou, Founder Director
LUNAC Therapeutics